by FimmCyte | Oct 18, 2024 | Insights
FimmCyte proudly claims a spot in the prestigious 2024 TOP 100 Swiss Startup Award, ranking #28 overall and achieving 4th place in the biotech sector. Selected by a panel of 100 leading investors and industry experts, this recognition highlights FimmCyte’s...
by FimmCyte | Oct 18, 2024 | Insights
FimmCyte, a pioneering women’s health biotech, announces an investment of 1 million CHF as a convertible loan from the UZH Life Sciences Fund (LSF). FimmCyte’s most advanced program is a non-hormonal disease modifying treatment for endometriosis. FimmCyte is a...
by FimmCyte | Oct 18, 2024 | Insights
FimmCyte AG, a pioneering women’s health biotech, announces the appointment of Dr. Markus Kalousek as chairperson of its Board of Directors effective November 1st, 2023. As an accomplished leader with over 25 years of experience in the Biotech and Pharma...
